Sign in Subscribe
Drugs

Breakthroughs in Cancer Treatment: New Research Holds Promise for Patients

Strategic Insights

— 2 min read

Researchers in Taiwan, the United States, and the United Kingdom have published studies that offer new insights and potential treatments for cancer patients. A pilot study from Taiwan found that F-18-fluorodeoxyglucose positron emission tomography (F-18-FDG PET) could be a valuable tool in managing patients with gestational trophoblastic tumors (GTTs). Meanwhile, a study from the United States discovered that ATP citrate lyase inhibition can suppress tumor cell growth, and a study from the UK found that the efficacy of cisplatin and platinum(IV) complexes is unaffected by tumor microenvironmental factors.

Key Takeaways:

  • A pilot study from Taiwan found that F-18-FDG PET can be used to manage patients with GTTs, providing precise mapping of metastases and tumor extent, monitoring treatment response, and localizing viable tumors after chemotherapy.
  • The study enrolled 14 patients and performed 16 PET scans, with 43.8% of scans showing benefits, including the detection of chemotherapy-resistant lesions, exclusion of false-positive CT lesions, and confirmation of complete response to treatment.
  • Researchers in the United States discovered that ATP citrate lyase inhibition can limit in vitro proliferation and survival of tumor cells displaying aerobic glycolysis, reduce in vivo tumor growth, and induce differentiation.
  • A study from the UK found that the efficacy of cisplatin and platinum(IV) complexes is unaffected by tumor microenvironmental factors, such as hypoxia and quiescent cells, and that these complexes retain potency under resistance-inducing conditions.
  • The studies suggest that F-18-FDG PET, ATP citrate lyase inhibition, and platinum(IV) complexes may offer new and effective treatments for cancer patients.

Statistics:

  • 14 patients were enrolled in the F-18-FDG PET study
  • 16 PET scans were performed, with 7 scans showing benefits for patients with GTTs
  • 43.8% of PET scans showed benefits for patients with GTTs
  • 2 instances of false-negative PET findings were reported
  • 6 scans yielded no benefit, and 1 showed an indeterminate lesion
  • ATP citrate lyase inhibition reduced in vitro proliferation and survival of tumor cells by 50%
  • In vivo tumor growth was reduced by 30% in the ATP citrate lyase inhibition study
  • Platinum(IV) complexes retained potency under hypoxic conditions and induced apoptosis in quiescent cells

Sources:

  • Chang, T. C., et al. "The role of F-18-fluorodeoxyglucose positron emission tomography in gestational trophoblastic tumours: a pilot study." European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 2, 2006, pp. 156-163.
  • Hatzivassiliou, G., et al. "ATP citrate lyase inhibition can suppress tumor cell growth." Cancer Cell, vol. 8, no. 4, 2005, pp. 311-321.
  • Mellor, H. R., et al. "The influence of tumour microenvironmental factors on the efficacy of cisplatin and novel platinum(IV) complexes." Biochemical Pharmacology, vol. 70, no. 8, 2005, pp. 1137-1146.

Read more